GLP-1 Drugs Show Promise for Treating Alcohol, Nicotine, and Other Addictions

Preclinical studies consistently demonstrate GLP-1 RAs reduce substance intake, attenuate reward-related behaviors, and suppress relapse-like responding across alcohol, nicotine, opioids, psychostimulants, and cannabinoids.

Narrative review of preclinical animal models and human observational studies on incretin-based therapies in addiction across multiple substance classes.

Addiction is a leading cause of death and disability globally, with limited effective pharmacotherapies. GLP-1 drugs are already widely available and could represent a breakthrough treatment if addiction benefits are confirmed in clinical trials.

The discovery that metabolic peptide signaling directly interacts with brain reward circuits has opened an entirely new therapeutic approach to addiction, bridging endocrinology and psychiatry in unprecedented ways.

Human evidence is largely observational. No published randomized controlled trials for addiction specifically. Animal models may not fully predict human addiction responses. Long-term effects of GLP-1 drugs on brain reward circuits are unknown.